An Evaluation of HER2 Expression Heterogeneity in Primary Tumors and Metastatic Lymph Nodes of Patients With Advanced Extramammary Paget's Disease: Prognostic and Therapeutic Implications
Cancer Medicine · 2025
DOI: 10.1002/cam4.71274 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cancer Medicine, 2025. Verfasst von Zhicheng Liu und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China. Hauptthemen laut MEDLINE: Paget Disease, Extramammary, Erb-b2 Receptor Tyrosine Kinases, Lymph Nodes, Biomarkers, Tumor. Die Arbeit nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Basic and Applied Basic Research Foundation of Guangdong Province, East Clinical Center of Oncology Foundation, Beijing Xisike Clinical Oncology Research Foundation.
Abstract (Originalsprache)
Background
HER2 expression in primary versus metastatic tumors in advanced Extramammary Paget's Disease (EMPD) remains inadequately characterized. This investigation aimed to assess HER2 expression heterogeneity between primary tumors and metastatic lymph nodes (LNs) in patients with advanced EMPD and to assess the prognostic value of HER2 expression and other pathological factors in determining the therapeutic value of HER2 targeting.
Methods
We included 170 patients diagnosed with primary EMPD. Survival outcomes were analyzed using multivariate Cox regression and log‐rank analysis, while inconsistencies in HER2 expression between primary and metastatic LNs were assessed using the kappa coefficient.
Results
HER2 high‐expression was observed in 71.6% of primary tumors and 68.8% of metastatic LNs, with high HER2 expression correlating with poorer overall survival. Multivariate Cox analysis identified advanced N stage and HER2 high‐expression in primary tumors as independent poor prognostic factors. In 31 paired samples, the discordance rate of HER2 status between primary tumors and corresponding LNs was 35.48% ( n = 11) (Kappa 0.11, 95% CI −0.26 to 0.47; p = 0.540), with 19.4% of cases showing a shift from high HER2 expression in primary tumors to low expression in metastatic LNs. Patients treated with disitamab vedotin had an 80% objective response rate (ORR) and a 100% disease control rate (DCR), with no adverse events above grade 3–4.
Conclusion
HER2 was frequently expressed in both primary tumors and metastatic LNs in EMPD patients, though heterogeneity was observed. HER2 status should be assessed in both primary and metastatic sites. Disitamab vedotin shows promise for treating HER2‐positive advanced EMPD, warranting further study.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Sun Yat-sen University Cancer Center, Guangzhou, China.
- State Key Laboratory of Oncology in Southern China, Guangzhou, China.
- Collaborative Innovation Center of Cancer Medicine, Guangzhou, China.
- Guangdong Provincial Clinical Research Center for Cancer, Guangzhou, China.
ORCID-Profile: Zhicheng Liu, Yanjun Wang
Förderung
- Basic and Applied Basic Research Foundation of Guangdong Province
- East Clinical Center of Oncology Foundation
- Beijing Xisike Clinical Oncology Research Foundation
- Fundamental Research Funds for the Central Universities, Sun Yat-sen University
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Liu, Z., Tan, X., Wu, Z., Tang, Y., Zhou, Q., Wei, W., Yang, C., Huang, L., Wang, Y., & Yao, K. (2025). An Evaluation of HER2 Expression Heterogeneity in Primary Tumors and Metastatic Lymph Nodes of Patients With Advanced Extramammary Paget's Disease: Prognostic and Therapeutic Implications. Cancer Medicine. https://doi.org/10.1002/cam4.71274
Vancouver
Liu Z, Tan X, Wu Z, Tang Y, Zhou Q, Wei W, et al. An Evaluation of HER2 Expression Heterogeneity in Primary Tumors and Metastatic Lymph Nodes of Patients With Advanced Extramammary Paget's Disease: Prognostic and Therapeutic Implications. Cancer Medicine. 2025. doi:10.1002/cam4.71274
BibTeX
@article{Liu2025,
author = {Liu, Zhicheng and Tan, Xingliang and Wu, Zhiming and Tang, Yi and Zhou, Qianghua and Wei, Wensu and Yang, Cong and Huang, Long and Wang, Yanjun and Yao, Kai},
title = {An Evaluation of HER2 Expression Heterogeneity in Primary Tumors and Metastatic Lymph Nodes of Patients With Advanced Extramammary Paget's Disease: Prognostic and Therapeutic Implications},
journal = {Cancer Medicine},
year = {2025},
doi = {10.1002/cam4.71274}
}
EUVIMED